New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year ...

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the ...

A research team at the University of Würzburg has gained new insights into the development of kidney tumors in young children. These enable a better risk assessment and could form the basis for ...

The idea of Shedeur Sanders going undrafted seemed preposterous when the 2025 NFL Draft week began. The Colorado star quarterback’s luster as a projected top-five pick may have diminished, but ...

Lower levels of AMP kinase led to higher levels of a protein called WT1, which in turn drove the formation of compounds that cause DNA damage. “We also demonstrate that hrMSCs lose expression of ...

WT1 factor is a promising biomarker for MRD monitoring, offering widespread applicability in AML cases and aiding pre-transplant clinical decisions. A study demonstrated that pre-transplant ...

Data showed substantial evidence of selective expansion of WT1-specific T cells, with anti-tumor activity and a favorable tolerability profile with no dose limiting toxicities (DLTs) observed.

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial ...

Real-world use of anti-EGFR therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) with outstanding preclinical anti ...